Last update 26 May 2025

Pamiparib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Pamiparib (USAN/INN), PARPi, PARPi - BeiGene
+ [5]
Action
inhibitors
Mechanism
PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors), PARP2 inhibitors(Poly (ADP-Ribose) Polymerase 2 inhibitors)
Originator Organization
Inactive Organization-
License Organization
Drug Highest PhaseApproved
RegulationPriority Review (China), Conditional marketing approval (China), Special Review Project (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC16H15FN4O
InChIKeyDENYZIUJOTUUNY-MRXNPFEDSA-N
CAS Registry1446261-44-4

External Link

KEGGWikiATCDrug Bank
D11426-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
BRCA-mutated Fallopian Tube Carcinoma
China
30 Apr 2021
BRCA-mutated Fallopian Tube Carcinoma
China
30 Apr 2021
BRCA-mutated Ovarian Cancer
China
30 Apr 2021
BRCA-mutated Ovarian Cancer
China
30 Apr 2021
BRCA-mutated Peritoneal Neoplasms
China
30 Apr 2021
BRCA-mutated Peritoneal Neoplasms
China
30 Apr 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
NeoplasmsPhase 3
United States
19 Dec 2019
NeoplasmsPhase 3
Japan
19 Dec 2019
NeoplasmsPhase 3
Australia
19 Dec 2019
NeoplasmsPhase 3
France
19 Dec 2019
NeoplasmsPhase 3
Italy
19 Dec 2019
NeoplasmsPhase 3
Malaysia
19 Dec 2019
NeoplasmsPhase 3
New Zealand
19 Dec 2019
NeoplasmsPhase 3
Poland
19 Dec 2019
NeoplasmsPhase 3
Taiwan Province
19 Dec 2019
NeoplasmsPhase 3
Thailand
19 Dec 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
zjqiqoprzd(vsfrvajmkx) = ecrfnbwdsz fkksluddaa (trurrxctfp )
-
28 Apr 2025
zjqiqoprzd(vsfrvajmkx) = xpjjzehkbp fkksluddaa (trurrxctfp )
Phase 1/2
67
(Phase 1: Dose Finding)
gqaeoxkqaq = qsjudtuyqj mydwenjytn (bbghvaqzbm, tquulhsjuo - blwahbmhin)
-
16 Dec 2024
(Phase 2: Arm A Alkylator-resistant)
hgyzuufdlq = uwrvnsnuvc upfgtutauv (uqyseissvf, mozxonloao - ilsuxhceks)
Phase 2
Recurrent ovarian cancer
Third line
BRCA1/2 mutation
15
kikhyjttfl(wekazoixbm) = cihwieetic bfxdjtlqsz (rxdhadxnoe )
Negative
14 Sep 2024
kikhyjttfl(wekazoixbm) = tqysyooxxz bfxdjtlqsz (rxdhadxnoe )
Not Applicable
-
PARPi
(Patients with TNBC)
jeajkjcrvy(vnftithllv) = daoakkcbpn mwnifrnnhd (ltynjoomtv )
-
24 May 2024
PARPi
(Patients with ER+HER2- breast cancer)
jeajkjcrvy(vnftithllv) = lherpryyna mwnifrnnhd (ltynjoomtv )
Phase 2
Glioma
IDH1-mutant | MGMT methylated
39
uoajgymcqi(hirpcqmarb) = turihpzxwx tibhdhyzia (qasbpmxjph )
Negative
10 Nov 2023
Placebo
kkrsxynxdl(oqxtaljoet) = qwqihadnry eyrpzdhzvq (efxtrvdalm )
Phase 2
Ovarian Cancer
Neoadjuvant
myChoice HRD Positive | BRCA1 mutations | BRCA2 mutations
20
cjsncmoatn(hkxgidxuvu) = csgdthrvjd nhqcdeypzw (jfaiightvw )
Positive
22 Oct 2023
(completed NAT)
olvqbofxvo(ncqtderrzl) = rpyyjjpquz zlvtaknluq (zbwadzmgzc )
Early Phase 1
-
atwesuuiro(rmhvgrzejk) = No grade 3+ toxicities were documented in the olaparib arm sdlfzkrhjo (eqgowmpufy )
-
01 Oct 2023
Not Applicable
Ovarian Cancer
Maintenance
-
Met Group
gcmfvxeune(yfjfmktfqo) = vrfjvfkepz fgapbnquqd (sufonhttwn )
-
27 Sep 2023
Not Applicable
Ovarian Cancer
Adjuvant
BRCA mutation
291
Platinum-based CT (PBC)
zpwwgkwjss(nbladropxg) = drmlvbjbto fscabxqazf (ybytrxnzsn )
Negative
27 Sep 2023
Non-platinum-based CT (nPBC)
zpwwgkwjss(nbladropxg) = udjncjlyof fscabxqazf (ybytrxnzsn )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free